09:45 AM EST - Aptose Biosciences Inc. : Announced today that the company management team will provide a clinical update on Saturday, June 10, at 12:00 PM EST / 6:00 PM CEST, in conjunction with EHA 2023 International Congress of the European Hematology Association in Frankfurt, Germany. The webcast event will include an interim review of Aptose’s lead compound tuspetinib, a myeloid kinase inhibitor, currently being tested as a monotherapy and in combination with venetoclax in the phase 1/2 APTIVATE trial. Aptose Biosciences Inc.
shares T.APS are trading unchanged at $0.56.
